Rune Labs, Inc., a developer of software that enables thedevelopment and delivery of the next wave of neuroscience therapeutics, today announced that itsecured a $5 million seed round led by DigiTx Partners. Earlier investors including TruVenturo, MomentVentures, Loup Ventures and Sabbatical Ventures participated in the round. Since the company’s founding in 2018, Rune Labs has raised a total of $7.3 million.

Rune Labs partners with leading med-tech and pharma companies to label, organize, and analyze braindata. Rune Labs is particularly focused on neuromodulation therapies such as Deep Brain Stimulation(DBS) and Transcranial Magnetic Stimulation (TMS). These device-based therapies generate a lot ofdata, including directly sensed brain signals. This data is currently underutilized in clinical trials and patient care as DBS and TMS manufacturers do not have a way to manage brain data at a large scale.

“Over the past two decades, we have witnessed tremendous improvements in neurostimulation devicesfor multiple neurologic conditions. What we are now seeing is the power of the information that could bederived from these devices. The technology Rune Labs is developing with neurologic and biometric data will optimize clinical care for many individuals with debilitating neurological and mental health conditions,”said David J. Kim, Managing Director, DigiTx Partners.

With Rune Labs’ platform, brain data can be sequenced both longitudinally for a single patient and acrossmultiple patients, studies, and centers to be analyzed with machine learning tools. Able to work withindustry leading systems from Medtronic, Abbott and others as well as mobile health apps and deviceslike Apple Watch, and fully HIPAA compliant, Rune Labs can enhance precision therapy delivery to patients to further personalize neuromodulation to better control their symptoms.

“This round of funding, following closely on last year’s, continues to validate our approach, technologyand strategy,” said Brian Pepin, founder and CEO, Rune Labs. “Strong financial backing from credible partners and world-class academic collaborators continues to position us to help better understand the brain in order to improve neuromodulation therapies that can improve the quality of patients’ lives.”

The company will use the funds to continue to invest in R&D and to develop additional products.

Strong Academic Partnerships

Rune Labs also announced an agreement to collaborate on research for University of Minnesota’s upcoming OCD Adaptive DBS studies, under Alik Widge, MD, Ph.D., Assistant Professor, Department ofPsychiatry at UM’s Medical School.

Over the past 12 months, Rune Labs has signed university collaborations with the following programs:UCSF’s Parkinson’s Adaptive DBS, University of Washington’s Parkinson’s DBS Remote-Monitoring,Mount Sinai’s Depression Adaptive DBS, Brown University and Baylor University’s OCD Adaptive DBS, and others."

The Rune Labs platform has made communication between data acquired from patients implanted atMount Sinai in New York with the analytic team at Georgia Tech nearly effortless and has proved essential to visualize the data and easily check data quality," said Helen S. Mayberg, M.D., Professor ofNeurology, Neurosurgery, Psychiatry, and Neuroscience, and Founding Director of the Nash FamilyCenter for Advanced Circuit Therapeutics at the Icahn School of Medicine at Mount Sinai.

“Rune Lab’s software platform lets us collect key metrics about patient motor state using a dedicatedApple Watch and companion app platform which then integrates and synchronizes with neural data all in a secure, HIPAA compatible cloud environment. With their software, we can view patient state andalgorithm performance in near real time and make decisions regarding adaptive DBS parameters, whichwe then update remotely,” said Ro'ee Gilron, Ph.D., a researcher at the UCSF Weill Institute ofNeurosciences and a member of Rune Labs’ scientific advisory board.